LUCAR-20S CAR-T cells / Medical School of Nanjing University, Legend Biotech - LARVOL DELTA

Study of LUCAR-20S in Patients With R/R NHL (clinicaltrials.gov) - P1; N=7; Terminated; Sponsor: The First Affiliated Hospital with Nanjing Medical University; N=34 ➔ 7; Trial completion date: Jan 2023 ➔ Dec 2021; Recruiting ➔ Terminated; Trial primary completion date: Oct 2022 ➔ Dec 2021; Both the sponsors and collaborator are considering terminating the study

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

Study of LUCAR-20S in Patients With R/R NHL (clinicaltrials.gov) - P1; N=34; Recruiting; Sponsor: Beijing Boren Hospital

New P1 trial • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

Study of LUCAR-20S in Patients With R/R NHL (clinicaltrials.gov) - P1; N=41; Recruiting; Sponsor: The First Affiliated Hospital with Nanjing Medical University; Initiation date: Oct 2019 ➔ Oct 2020

Clinical • Trial initiation date • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma